Regenerative ECM Platform
Ischemic Tissue Repair
Pre-clinicalActive
Key Facts
About Ventrix
Founded in 2013, Ventrix is a private, preclinical-stage biotech pioneering ECM-based biotherapeutics. The company's core hypothesis is that delivering tissue-specific extracellular matrix can restart stalled repair processes by providing the essential architectural and biochemical framework for cellular regeneration. Targeting significant unmet needs in cardiovascular repair, Ventrix aims to translate the fundamental biology of the ECM into a new therapeutic modality. As a pre-revenue company, its success hinges on advancing its lead programs through clinical validation.
View full company profile